Impact of a Pilot Outreach Program upon Provider Awareness and Prescribing of a Concerning Opioid Combination Regimen

Thursday, February 22, 2018
Publication cover image
Briana Santaniello, PharmD, MBA
Magellan Rx Management
Thomas Pomfret, PharmD, MPH, BCPS
University of Massachusetts Medical School
Mark Tesell, PharmD, BCPS
University of Massachusetts Medical School
Caroline J. Alper, MD
University of Massachusetts Medical School
Karen Clements, ScD
University of Massachusetts Medical School
Vincent Palumbo, MBA, BS, RPh
University of Massachusetts Medical School
Kimberly Lenz, PharmD
University of Massachusetts Medical School
Paul L. Jeffrey, PharmD
University of Massachusetts Medical School

This pilot program was developed in response to a drug utilization review within a large Medicaid population that revealed some hazardous practices. Co-prescribing of opioids with benzodiazepines, gabapentin, and other stimulants occurred in more than 500 members, putting them at risk for additive central nervous system depression, misuse, abuse, and death from overdose.

The poster presentation outlines the objectives, methods, and results of a telephonic outreach program that addressed these safety concerns. It captures prescriber awareness of the presence and risks of potentially deadly medication combinations among members in their care, with some intriguing results.

Our experts provide health plans with framework and support to address the opioid epidemic head on with robust opioid medication management programs, evidence-based clinical guidelines, and prescriber outreach. Our interdisciplinary team’s innovative approach helps health plans decrease inappropriate opioid usage and while ensuring members maintain access to appropriate pain management. This presentation was given at the American Drug Utilization Review Society (ADURS) conference February 22-24, 2018 in Scottsdale, Arizona.

Conference 
American Drug Utilization Review Society Conference 2018